FDA Approval: Zenocutuzumab for NRG1+ NSCLC

Podcast | English | 2024 | 20 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion.

Podcast Hosts:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Alison Schram, MD, Assistant Attending Physician adn Section Head of Oral Therapeutics in Early Drug Development, Memorial Sloan Kettering Cancer Center, New York , NY, USA